Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
Emory University
Georgetown University
Hoosier Cancer Research Network
MedSIR
Mayo Clinic
Emory University
Medstar Health Research Institute
University of California, San Diego
Piedmont Cancer Institute
Medical College of Wisconsin
Fox Chase Cancer Center
Masonic Cancer Center, University of Minnesota
Mayo Clinic
University of Rochester
Virginia Commonwealth University
Zhejiang University
Roswell Park Cancer Institute
Washington University School of Medicine